Zanubrutinib: past, present, and future
- Author(s)
- Tam, CS; Munoz, JL; Seymour, JF; Opat, S;
- Journal Title
- Blood Cancer Journal
- Publication Type
- Review
- Abstract
- In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be approved, and it changed the standard-of-care treatment for diseases such as chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom macroglobulinemia, improving efficacy outcomes and safety compared to chemotherapy. In this article, we review the development of zanubrutinib, a next-generation BTK inhibitor, from molecular design to patient-related outcomes. We start this journey by providing insights into the discovery of BTK and the physiologic, genetic, and molecular characterization of patients lacking this kinase, together with the brief treatment landscape in the era of chemo-immunotherapies. Zanubrutinib was originally developed by applying a structure-activity strategy to enhance the specificity as well as enzymatic and pharmacokinetic properties. Preclinical studies confirmed greater specificity and better bioavailability of zanubrutinib compared with that of ibrutinib, which supported the initiation of clinical trials in humans. Preliminary clinical results indicated activity in B-cell malignancies together with an improved safety profile, in line with less off-target effects described in the preclinical studies. The clinical program of zanubrutinib has since expanded significantly, with ongoing studies in a wide range of hemato-oncological diseases and in combination with many other therapies. Zanubrutinib currently is approved for various B-cell malignancies in multiple countries. This story highlights the importance of multidisciplinary collaborative research, from bench to bedside, and provides an example of how the commitment to finding improved treatment options should always run parallel to patient care.
- Publisher
- Springer Nature
- Keywords
- Humans; Adult; *Pyrazoles/pharmacology/therapeutic use; B-Lymphocytes; Immunotherapy; *Leukemia, Lymphocytic, Chronic, B-Cell
- Department(s)
- Clinical Haematology
- PubMed ID
- 37696810
- Publisher's Version
- https://doi.org/10.1038/s41408-023-00902-x
- Open Access at Publisher's Site
https://doi.org/10.1038/s41408-023-00902-x- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-11-21 05:54:34
Last Modified: 2023-11-21 05:55:40